IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
Essen Biotech
Hadassah Medical Organization
Medicenna Therapeutics, Inc.
Vall d'Hebron Institute of Oncology
Erasmus Medical Center
Sheba Medical Center